Skip to main content

When

Dec. 4, 2026, Noon
Image
BME seminar logo

Friday, December 4, 2026, at 12:00 p.m.

Sammer Bajikar
Assistant Professor
Departments of Cell Biology and Biomedical Engineering
University of Virginia

"Human Stem Cells and Computational Models to Understand the Brain During Neurodevelopmental Disorders"

Keating 103 | Zoom link

Image
person with short black hair, wearing blue suit, shirt and striped tie


Abstract: Nearly 1 in 20 children in the United States is affected by a neurodevelopmental disorder (NDD). For many of these children, genetic testing has identified the specific gene mutations responsible for their disorder. Despite this genetic insight, targeted treatments remain largely unavailable. One gene critical for normal brain development is methyl-CpG-binding protein 2 (MECP2). Loss-of-function mutations in MECP2 cause Rett syndrome, a severe childhood neurological disorder, whereas mutations that increase MECP2 function cause a distinct disorder known as MECP2 duplication syndrome. Thus, MECP2 is a “Goldilocks” gene, in which both too little and too much activity is detrimental to brain health. Strikingly, restoring appropriate MECP2 gene dosage is sufficient to reverse neurological symptoms in preclinical models of both Rett syndrome and MECP2 duplication syndrome. Leveraging concepts from systems and signals engineering, we identified molecular mediators that contribute to disease pathogenesis and restored brain function. Through this approach, we discovered that MECP2 directly regulates growth differentiation factor 11 (GDF11), a member of the TGF-β signaling family. We further identified GDF11 as an important regulator of brain health and a potential therapeutic target for MECP2-related disorders. Building on these findings, we are developing patient-derived induced pluripotent stem cell (iPSC) models of MECP2 disorders to establish a scalable platform for evaluating therapeutic strategies. In this seminar, we will discuss important considerations for using iPSCs to study NDDs. Ultimately, our future work seeks to extend the principles and approaches developed through our study of MECP2 disorders to additional genetic NDDs.

Bio: Sammer Bajikar received his PhD in biomedical engineering from the University of Virginia, where he developed experimental and computational approaches to study gene expression heterogeneities in cancer in the lab of Kevin Janes. He then pivoted to a postdoctoral fellowship in molecular and human genetics at Baylor College of Medicine in the lab of Huda Zoghbi, where he applied engineering concepts to study childhood neurodevelopmental disorders. He returned to UVA in 2024 as an assistant professor in the Departments of Cell Biology and Biomedical Engineering, where his lab continues to work at the interface of engineering, systems biology and neuroscience in the pursuit of understanding the pathogenesis of neurodevelopmental disorders to develop treatments for these patients.